New Challenges in the Management of Pulmonary Toxicities

Pulmonary function is important to maintaining homeostasis and dysfunction can result in life-threatening complications. There is a need to discuss the incidence, prevention, and management of pulmonary toxicities given that numerous cancer treatments have the potential to cause pulmonary dysfunction. Clinician education on this topic can help them provide optimal care for patients experiencing pulmonary toxicity.

Target Audience

This program is designed to meet the educational needs of oncology nurses who manage patients with cancer. 

Learning Objectives

Following this activity, participants should be able to:

  • Describe the incidence and impact of pulmonary toxicities in cancer treatment.
  • Identify the cancer therapies that contribute to the development of pulmonary toxicities.
  • Explain management strategies to prevent and mitigate pulmonary toxicities. 
Additional information
Supporters: 

This activity is supported by educational grants from Genentech, a member of the Roche Group; Novartis; and Seagen. This activity is supported by independent educational grants from Incyte Corporation and Merck & Co., Inc. This activity is supported by an independent medical educational grant from ADC Therapeutics. This activity is supported by a grant from Pfizer Inc.

Course summary
Available credit: 
  • 0.75 ANCC contact hours
    • 0.50 ANCC Pharmacology Contact Hours
  • 0.75 Participation
Course opens: 
05/15/2023
Course expires: 
03/01/2024
Cost:
$0.00

Rachael Fornwalt, AG-ACNP
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions 

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Rachael Fornwalt, AG-ACNP

NCCN Staff Disclosures 

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 0.75 contact hour, 0.50 of which are pharmacotherapeutic contact hours.

Available Credit

  • 0.75 ANCC contact hours
    • 0.50 ANCC Pharmacology Contact Hours
  • 0.75 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing